» Articles » PMID: 7780971

Bcl-xL is Expressed in Neuroblastoma Cells and Modulates Chemotherapy-induced Apoptosis

Overview
Journal Cancer Res
Specialty Oncology
Date 1995 Jun 15
PMID 7780971
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

bcl-x is a new member of the bcl-2 gene family and is highly expressed in neural tissues. The present study was designed to determine the expression of the bcl-x gene products in neuroblastoma (NB) and their role in the modulation of chemotherapy-induced apoptosis. Twenty-seven NB cell lines were screened by quantitative immunoprecipitation for Bcl-xL, Bcl-xS, and Bcl-2 expression. None of the cell lines expressed Bcl-xS. Twenty-four of 27 (88%) of the NB cell lines expressed Bcl-xL and 21 of 27 (78%) were positive for Bcl-2. The level of Bcl-xL and Bcl-2 expression was variable among the lines analyzed. Bcl-2 expression was restricted to cells of chromaffin lineage, whereas Bcl-xL was seen in both chromaffin and nonchromaffin lines. To determine whether Bcl-xL could mediate chemotherapy resistance, a NB cell line expressing negligible levels of Bcl-xL was transfected with a bcl-xL expression vector, and unique clones were generated expressing variable levels of Bcl-xL. Cells were treated either with cisplatinum (CP), 4-hydroperoxy-cyclophosphamide (4-HC), or etoposide (VP-16) to induce apoptosis, and cell viability and DNA degradation were determined. Following treatment with CP or 4-HC, Bcl-xL-expressing cells showed significantly increased viability as compared to vector-transfected controls (P < 0.005). Flow cytometric analysis of propidium iodide-stained nuclei following CP or 4-HC treatment revealed significantly increased DNA degradation in controls as compared to Bcl-xL-expressing lines (P < 0.004). DNA analysis by pulsed-field gel electrophoresis revealed high molecular weight (approximately 40 kb) DNA degradation in controls, whereas the DNA in cells expressing Bcl-xL was largely intact. In contrast to CP and 4-HC, results with VP-16 revealed a short-term delay in the onset of apoptosis in Bcl-xL-expressing cells with no long-term survival advantage. The results of these studies indicate Bcl-xL is expressed in NB cells and functions in a manner analogous to Bcl-2 by inhibiting chemotherapy-induced apoptosis.

Citing Articles

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y Signal Transduct Target Ther. 2024; 9(1):132.

PMID: 38763973 PMC: 11102923. DOI: 10.1038/s41392-024-01823-2.


Targeting the apoptosis pathway to treat tumours of the paediatric nervous system.

Fitzgerald M, OHalloran P, Connolly N, Murphy B Cell Death Dis. 2022; 13(5):460.

PMID: 35568716 PMC: 9107479. DOI: 10.1038/s41419-022-04900-y.


Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells.

Gong B, Zhang J, Hua Z, Liu Z, Thiele C, Li Z Front Oncol. 2021; 11:686898.

PMID: 34322387 PMC: 8311598. DOI: 10.3389/fonc.2021.686898.


A direct comparison of selective BH3-mimetics reveals BCL-X, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma.

Bierbrauer A, Jacob M, Vogler M, Fulda S Br J Cancer. 2020; 122(10):1544-1551.

PMID: 32203216 PMC: 7217842. DOI: 10.1038/s41416-020-0795-9.


Destined to Die: Apoptosis and Pediatric Cancers.

Choo Z, Loh A, Chen Z Cancers (Basel). 2019; 11(11).

PMID: 31652776 PMC: 6893512. DOI: 10.3390/cancers11111623.